Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries대규모 합성 파지 라이브러리에서 다양한 중화 SARS-CoV-2 항체의 신속한 발견Article Published on 2022-01-012022-09-11 Journal: mAbs [Category] 변종, 진단, [키워드] Alpha antibody Beta bind binding candidate characterization complementarity-determining region coronavirus disease Coronavirus disease 2019 COVID-19 Delta disease epitope Features Gamma global public health Health crisis high affinity IgG in vitro in vivo limit mAbs monoclonal antibodies monoclonal antibody N-terminal domain Neutralizing Neutralizing activity neutralizing antibody neutralizing SARS-CoV-2 antibody passive immunization Rapid Receptor-binding domain retained S1 subunit SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 S1 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants spike glycoprotein Spike protein synthetic libraries synthetic libraries. the receptor-binding domain the S1 subunit therapeutic options therapeutic strategy unique while [DOI] 10.1080/19420862.2021.2002236 PMC 바로가기 [Article Type] Article
Correlation of vaccine‐elicited antibody levels and neutralizing activities against SARS‐CoV‐2 and its variantsSARS-CoV-2 및 그 변이체에 대한 백신 유도 항체 수준과 중화 활성의 상관관계Letter to Editor Published on 2021-12-192022-09-10 Journal: Clinical and Translational Medicine [Category] SARS, 변종, 진단, [키워드] antibody Neutralizing activity SARS‐CoV‐2 variant [DOI] 10.1002/ctm2.644 PMC 바로가기 [Article Type] Letter to Editor
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection HistoryBNT162b2-백신 접종 및 감염 이력에 따른 Anti-SARS-CoV-2 면역글로불린 아이소타입 및 바이러스 변이체에 대한 중화 활성Immunology Published on 2021-12-172022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, 치료기술, 치료법, [키워드] activity Against anti-RBD Anti-RBD IgG antigen-specific antibody assays B.1 bead BNT162b2 BNT162b2 vaccine both group both groups coronavirus COVID-19 COVID-19 disease COVID‐19 cytopathic delta variant Delta variants disease domain dose expression pattern Fluorescence followed by Gamma highest history IgA IgG IgG levels IgM immunoassay Immunoglobulin immunoglobulins individual maximum mRNA vaccine multiplex immunoassay naïve neutralization Neutralization assay Neutralizing activity neutralizing capacity neutralizing titers Nucleocapsid proteins plasma post-symptom onset provided RBD Result SARS-CoV-2 SARS-CoV-2 antigen Serological assay single vaccine subject subjects suggested Support symptom onset three groups vaccination Vaccine variants Vero E6 Viral Viral antigen was determined [DOI] 10.3389/fimmu.2021.793191 PMC 바로가기 [Article Type] Immunology
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants이종 Chadox1 NCOV-19 및 BNT162B2 프라임-부스트 백신 접종은 유능한 SARS-COV-2 변이체에 대한 강력한 중화 항체 반응 및 T 세포 반응성을 유도합니다.Clinical Trial Published on 2021-12-172022-08-13 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] addition Administered Adverse reactions All participants Alpha analysed antibody titres ART Arts B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta BNT162b2 boost CD4 CD8 Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 COVID-19 vaccination Delta dominant elicit elicited European evaluate finding followed by foundation funding Gamma Germany Heterologous heterologous vaccination homologous Horizon humoral immune immune responses Immunity immunogenic Immunological response immunological responses individual induce Lower median mRNA-based vaccine mRNA-based vaccines nCoV neutralization neutralized Neutralizing activity Neutralizing antibody response no difference offer P.1 participant peptide peptides prevalent Protective reactive reactivity reactogenicity receiving recognize regimen Research resulting retained Robert Koch SARS-CoV-2 spike peptide SARS-CoV-2 variant SARS-CoV-2 variants Science sera Serious Adverse Event Serious Adverse Events serological data significantly Symptom T cell T cells tested titre union vaccination variant variants variants of concern Wuhan Wuhan-Hu-1 [DOI] 10.1016/j.ebiom.2021.103761 PMC 바로가기 [Article Type] Clinical Trial
Deep dissection of the antiviral immune profile of patients with COVID-19COVID-19 환자의 항바이러스 면역 프로파일에 대한 심층 분석Article Published on 2021-12-162022-09-10 Journal: Communications Biology [Category] SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] Anti-RBD antibodies Anti-S1 anti-SARS-CoV-2 humoral antibody Antiviral antiviral antibodies assist B.1.351 Beta binding CD4 Cell coronavirus coronavirus 2 COVID-19 patient COVID-19 patients Critically ill deep Epitopes evidenced expressing finding growth factor help Humoral immunity identify IgG antibody IgG1 IgG3 Immune profile immune response immune responses immunodominant LAG-3 linear epitope Mutation N proteins Neutralizing activity nucleocapsid occur Patient patients patients with COVID-19 proportion Protein Proteins RBD Receptor-binding domain reduced respiratory responses against S protein S protein-specific antibody SARS-CoV-2 SARS-CoV-2 protein SARS-CoV-2 proteins screened severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly significantly higher specific antibodies specificity Subtypes suppressor cells T cell T cells TGF-β the receptor-binding domain transforming growth factor Vaccines variant viral infection [DOI] 10.1038/s42003-021-02852-1 PMC 바로가기 [Article Type] Article
Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi ArabiaReview Published on 2021-12-142022-10-31 Journal: International journal for equity in health [Category] COVID-19, [키워드] applied approach country COVID-19 COVID-19 case COVID-19 patients Critical cross-reactivity described develop development Effectiveness ELISA ELISAs Epidemiology evaluated full-length healthcare healthcare worker healthy blood donor healthy blood donors highest highlight hospital IgG IgM Immunity immunoassay immunoassays lack Local lockdown micro-neutralization assay microneutralization Neutralizing activity New Non-COVID-19 patients nucleocapsid other coronaviruses peaked polymerase chain Population protocol quarantine report reported RT-PCR S1 subunit Sample size SARS-CoV-2 SARS-CoV-2 specific antibody Saudi Arabia sensitivity serology Seroprevalence specificity Spread statistical analyses study period the immunoassay Vaccine Variation [DOI] 10.3390/healthcare9121730 PMC 바로가기 [Article Type] Review
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 VariantsSARS-CoV-2 변이체에 대한 강력하고 보호적인 인간 중화 항체Immunology Published on 2021-12-132022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus 2 Against Alpha Analysis antibody approved Beta body weight Brain conserved controls coronavirus cryo-EM crystal death decrease E484K Emergency use authorization epitope EUA Human human neutralizing antibody in vivo protection individual infected with SARS-CoV-2 Infectious virus injection Isolation K417N lung Lung pathology mAbs manifested monoclonal antibodies monoclonal antibody Neutralizing Neutralizing activity potent prophylactic treatment Receptor-binding domain reduced respiratory responsible SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Spike protein Spread the receptor-binding domain the spike protein Vaccine variant variants of concern [DOI] 10.3389/fimmu.2021.766821 PMC 바로가기 [Article Type] Immunology
Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIVHIV 감염자의 SARS-CoV-2 감염 및 Ad26.CoV2.S 예방접종의 면역원성Major Article Published on 2021-12-102022-09-10 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, [키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Ad26.CoV2.S vaccines African clinical trial COVID-19 disease death decrease Delta delta variant disease Effect elicit enrolled examined Frequency HCW Health care Health care worker health care workers higher risk highest HIV HIV infection HIV viremia HIV-negative immunogenicity individuals infected with SARS-CoV-2 Live virus neutralization Neutralization assay neutralization capacity Neutralizing activity no decrease non-responder non-responders participant Participants people living with HIV people with HIV PLWH reduced reduction in reported responders Result SARS-CoV-2 SARS-COV-2 infection South suppression the strongest vaccination Vaccine Viremia with HIV [DOI] 10.1093/cid/ciab1008 PMC 바로가기 [Article Type] Major Article
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virusArticle Published on 2021-12-092022-10-04 Journal: Nature Medicine [Category] 비임상, 임상, 치료제, [키워드] Administered Adverse antibody approved arthralgia Arthritis cause characterized Chikungunya virus clinical trial Concentration conducted detectable disease dose dose-dependent Effect evaluate evaluated Ex vivo expression Fever functional healthy Human IgG IgG level immunocompromised individual Immunoglobulin in vivo Infant Infection Infectious diseases interim analysis intravenous knowledge Messenger RNA Mild moderate monoclonal monoclonal antibody mRNA mRNA-based Neutralizing Neutralizing activity neutralizing antibody offer participant patients phase 1 trial Placebo placebo-controlled plasma concentration predicted Preventive medicine Primary outcome Randomized Rash serum severity single dose therapeutic therapeutic use therapy Tolerability Treatment Trial viral infection [DOI] 10.1038/s41591-021-01573-6 PMC 바로가기 [Article Type] Article
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together밤라니비맙 단독 또는 밤라니비맙과 에테세비맙을 함께 투여받은 경증 또는 중등도 COVID-19 환자에서 SARS-CoV-2에 대한 내인성 항체 반응Clinical Trial Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 임상, 진단, 치료법, 치료제, [키워드] Administered antibodies Antibody Response Antibody titer Antibody titers antigenic B.1.351 bamlanivimab baseline Beta Beta variant binding breadth clinically Cohort collected correlated COVID-19 Day decrease develop domain Effect endogenous epitope Epitopes etesevimab evade Factor full-length Hospitalization humoral immune response in viral investigated longitudinal mAb mAbs Mild Moderate COVID-19 monoclonal antibody monotherapy Mortality multiplex mutant N-terminal domain Neutralization assay Neutralizing activity neutralizing monoclonal antibodies nucleocapsid protein Patient performed Placebo Received receiving recipient reduced reductions in response Result SARS-CoV-2 SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 pseudovirus sera serology serum sample specificity subsequent titer titers treated Treatment Trial variant Viral Viral load [DOI] 10.3389/fimmu.2021.790469 PMC 바로가기 [Article Type] Clinical Trial